Mammalian target of rapamycin signaling in the podocyte

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 3, 2012, Pages 251-257

  Inoki, Ken ^a   Huber, Tobias B ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

autophagy; diabetic nephropathy; glomerulopathy; mTOR; podocyte; proteinuria; rapamycin

Indexed keywords

AUTOPHAGY PROTEIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NEPHRIN;

AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; CELL AGING; CELL LOSS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; GLOMERULOPATHY; GOLGI COMPLEX; HUMAN; LYSOSOME; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CARRIER PROTEINS; HUMANS; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; PODOCYTES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84859632390     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283520f38     Document Type: Review

References (67)

1. Simons M, Hartleben B, Huber TB. Podocyte polarity signalling. Curr Opin Nephrol Hypertens 2009; 18:324-330.
2. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71:1205-1214. (Pubitemid 46884251)
3. Fogo AB. The targeted podocyte. J Clin Invest 2011; 121:2142-2145.
4. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immuno-suppressant rapamycin in yeast. Science 1991; 253:905-909. (Pubitemid 21917235)
5. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273:239-242. (Pubitemid 26285890)
6. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-27537.
7. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
8. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78:35-43. (Pubitemid 24228298)
9. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994; 91:12574-12578.
10. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457-468. (Pubitemid 35284167)
11. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol 2004; 6:1122-1128. (Pubitemid 39468014)
12. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-1302. (Pubitemid 38991819)
13. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-175. (Pubitemid 34876545)
14. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-189. (Pubitemid 34876546)
15. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484. (Pubitemid 43199434)
16. Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146:408-420.
17. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101. (Pubitemid 40262113)
18. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoidinduced protein kinase 1 (SGK1). Biochem J 2008; 416:375-385.
19. Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008; 27:1932-1943.
20. Ikenoue T, Inoki K, Yang Q, et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 2008; 27:1919-1931.
21. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310-322.
22. Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320:1496-1501. (Pubitemid 351929429)
23. Inoki K, Li Y,XuT,Guan KL.RhebGTPase is a direct target ofTSC2GAPactivity and regulates mTOR signaling. Genes Develop 2003; 17:1829-1834. (Pubitemid 36944560)
24. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15:702-713. (Pubitemid 40599924)
25. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25:903-915. (Pubitemid 46436534)
26. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003; 67:87-96. (Pubitemid 38312854)
27. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355:1345-1356.
28. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol 2002; 4:648-657. (Pubitemid 34993700)
29. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121:179-193. (Pubitemid 40546387)
30. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20:2493-2502.
31. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011; 79:502-511.
32. Rangan GK, Coombes JD. Renoprotective effects of sirolimus in nonimmune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2007; 22:2175-2182. (Pubitemid 47244694)
33. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuriaassociated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16:2063-2072. (Pubitemid 41716437)
34. Naumovic R, Jovovic D, Basta-Jovanovic G, et al. Effects of rapamycin on active Heymann nephritis. Am J Nephrol 2007; 27:379-389. (Pubitemid 47077202)
35. Ito N, Nishibori Y, Ito Y, et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest 2011; 91:1584-1595.
36. Kurayama R, Ito N, Nishibori Y, et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest 2011; 91:992-1006. Identification of LAT2 as potential upstream regulator of mTOR activation in podocytes.
37. Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27:495-502. (Pubitemid 47482007)
38. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20:2490-2492.
39. Torras J, Herrero-Fresneda I, Gulias O, et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24:3632-3640.
40. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2:326-333.
41. Munivenkatappa R, Haririan A, Papadimitriou JC, et al. Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF. Histol Histopathol 2010; 25:189-196.
42. Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragmassociated proteins. Transplantation 2011; 91:997-1004.
43. Biancone L, Bussolati B, Mazzucco G, et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010; 10:2270-2278.
44. Vollenbroker B, George B, Wolfgart M, et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009; 296:F418-F426.
45. Vogelbacher R, Wittmann S, Braun A, et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84:1492-1499. (Pubitemid 350294725)
46. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121:2181-2196. Genetic dissection of the role of mTORC1 in diabetic nephropathy.
47. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121:2197-2209. Genetic dissection of the role of mTOR complexes for podocyte maintenance and disease.
48. Lu MK, Gong XG, Guan KL. mTOR in podocyte function: is rapamycin good for diabetic nephropathy? Cell Cycle 10:3415-3416.
49. Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol 2011; 170:36-47.
50. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52:1023-1030. (Pubitemid 36384273)
51. Luo ZF, Feng B, Mu J, et al. Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation. Toxicol Appl Pharmacol 2010; 246:49-57.
52. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22:132-139.
53. Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010; 120:1084-1096. Genetic dissection of the role of autophagy in podocyte maintenance and disease.
54. Weide T, Huber TB. Implications of autophagy for glomerular aging and disease. Cell Tissue Res 2011; 343:467-473.
55. Narita M, Young AR, Arakawa S, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 2011; 332:966-970. Identification of the spatial coupling of autophagy and mTOR signaling, which might have important implications for podocyte homeostasis.
56. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21:1691-1701.
57. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707-716. (Pubitemid 36278589)
58. Cina DP, Onay T, Paltoo A, et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2011. [Epub ahead of print] Role of mTOR for autophagic flux in podocytes.
59. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14:290-298. (Pubitemid 351347919)
60. Dai C, Stolz DB, Kiss LP, et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20:1997-2008.
61. Kato H, Gruenwald A, Suh JH, et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem 2011; 286:26003-26015.
62. Shkreli M, Sarin KY, Pech MF, et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat Med 2011; 18:111-119. Identification of Wnt signaling as regulator of podocyte cell cycle control.
63. Simons M, Huber TB. Old friends form alliance against podocytes. Kidney Int 2011; 80:1117-1119.
64. Wang D, Dai C, Li Y, Liu Y. Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int 2011; 80:1159-1169.
65. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126:955-968. (Pubitemid 44310775)
66. Karbowniczek M, Zitserman D, Khabibullin D, et al. The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 2010; 120:93-102.
67. Ma J,Meng Y, Kwiatkowski DJ, et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 2010; 120:103-114.